868836-41-3

Upstream product

• 868835-87-4 N-{4-[(N,N-dimethylamino)benzyl]butyl}phthalimide 
• 41624-92-4 methyl 8-chloro-8-oxooctanoate 
• 99008-43-2 2-(4-aminobutyl)isoindoline-1,3-dione 
• 66917-06-4 N-(4-azidobutyl)phthalimide 
• 5394-18-3 2-(4-bromobutyl)isoindoline-1,3-dione 

Downstream Products

• 868836-45-7 7-{4-[N-(tert-butyloxycarbonyl)amino]butyl}-{N-[4-N,N-(dimethyl)aminobenzyl]carbamoyl}heptanohydroxamic acid 
• 913174-01-3 7-{{4-[N-(tert-butyloxycarbonyl)amino]butyl}-{N-[4-N,N-(dimethyl)aminobenzyl]carbamoyl}}heptanoic acid 
• 868836-43-5 7-{4-[N-(tert-butyloxycarbonyl)amino]butyl}-{N-[4-N,N-(dimethyl)aminobenzyl]carbamoyl}heptanoic acid 

Relevant academic research and scientific papers

HISTONE DEACETYLASE INHIBITORS

The present invention provides novel HDAC inhibitors and methods of treating diseases using the same.

Alkyl-substituted polyaminohydroxamic acids: A novel class of targeted histone deacetylase inhibitors

The reversible acetylation of histones is critical for regulation of eukaryotic gene expression. The histone deacetylase inhibitors trichostatin (TSA, 1), MS-275 (2) and suberoylanilide hydroxamic acid (SAHA, 3) arrest growth in transformed cells and in h